Drug discovery is currently in an exciting phase where conventional methodologies are being ably complemented by ‘omics’ approaches due, in part, to the greater accessibility of the newest generation of high-throughput platforms and technologies. At the Cancer Discovery Biology Laboratory, work is done towards making the identification of oncology clinical biomarkers more feasible through state-of-the-art pharmacogenomic and proteomic technologies as well as bioinformatic approaches.
In addition, the lab facilitates the early drug discovery screen of novel small molecules through rational studies that help identify robust lead molecules in oncology. The lab also integrates drug metabolism and disposition studies with advanced pharmacometric approaches to better appreciate the pharmacokinetics and pharmacodynamics of candidate drug molecules in oncology.
